Исландия -
исландский -
LYFJASTOFNUN (Icelandic Medicines Agency)
conoxia lyfjagas undir þrýstingi 100 %
linde gas - oxygenium - lyfjagas undir þrýstingi - 100 %
Исландия -
исландский -
LYFJASTOFNUN (Icelandic Medicines Agency)
marcain stungulyf, lausn 2,5 mg/ml
aspen pharma trading limited - bupivacainum hýdróklóríð - stungulyf, lausn - 2,5 mg/ml
Исландия -
исландский -
LYFJASTOFNUN (Icelandic Medicines Agency)
marcain stungulyf, lausn 5 mg/ml
aspen pharma trading limited - bupivacainum hýdróklóríð - stungulyf, lausn - 5 mg/ml
Исландия -
исландский -
LYFJASTOFNUN (Icelandic Medicines Agency)
marcain adrenalin stungulyf, lausn 2,5 mg/ml+5 míkróg/m
aspen pharma trading limited - bupivacainum hýdróklóríð; adrenalinum bítartrat (epinephrinum bítartrat) - stungulyf, lausn - 2,5 mg/ml+5 míkróg/m
Исландия -
исландский -
LYFJASTOFNUN (Icelandic Medicines Agency)
marcain adrenalin stungulyf, lausn 5 mg/ml+5 míkróg/ml
aspen pharma trading limited - bupivacainum hýdróklóríð; adrenalinum bítartrat (epinephrinum bítartrat) - stungulyf, lausn - 5 mg/ml+5 míkróg/ml
Исландия -
исландский -
LYFJASTOFNUN (Icelandic Medicines Agency)
xylocain stungulyf, lausn 10 mg/ml
aspen pharma trading limited - lidocainum hýdróklóríð - stungulyf, lausn - 10 mg/ml
Исландия -
исландский -
LYFJASTOFNUN (Icelandic Medicines Agency)
xylocain stungulyf, lausn 20 mg/ml
aspen pharma trading limited - lidocainum hýdróklóríð - stungulyf, lausn - 20 mg/ml
Исландия -
исландский -
LYFJASTOFNUN (Icelandic Medicines Agency)
xylocain adrenalin stungulyf, lausn 10 mg/ml+5 míkróg/ml
aspen pharma trading limited - lidocainum hýdróklóríð; adrenalinum bítartrat (epinephrinum bítartrat) - stungulyf, lausn - 10 mg/ml+5 míkróg/ml
Европейский союз -
исландский -
EMA (European Medicines Agency)
pylclari
curium pet france - piflufolastat (18f) - blöðruhálskirtli - greining geislavirkja - Þetta lyf er eingöngu ætlað til greiningar. pylclari is indicated for the detection of prostate-specific membrane antigen (psma) positive lesions with positron emission tomography (pet) in adults with prostate cancer (pca) in the following clinical settings:primary staging of patients with high-risk pca prior to initial curative therapy,to localize recurrence of pca in patients with a suspected recurrence based on increasing serum prostate-specific antigen (psa) levels after primary treatment with curative intent. pylclari is indicated for use with positron emission tomography (pet).